Neutropenia Treatment Market By Drug Type (G-CSF, GM-CSF, Antibiotics, Antifungal, Antiviral), By Pipeline Analysis (Plinabulin - Phase 2/3, EC-18 - Phase 2, SPI-2012 - Phase 3, rHSA-GCSF 2.4mg - Phase 2, Probio-Fix Inum - Phase 2, Pegteograstim - Phase 2, F-627 - Phase 3, Astragalus polysaccharides 500 mg - Phase 2, Leucostim - Phase 3, myelo001 - Phase 3, Romyelocel-L - Phase 3) - Growth, Future Prospects and Competitive Analysis, 2019-2027

Neutropenia treatment accounted for a market value of US$ 11,279.2 million in 2018 and is projected to grow at a CAGR of 5.0% during the forecast period from 2019 to 2027. In neutropenia, the count of neutrophils falls, giving rise to compromised immunity and further increasing the risk of infection. Neutropenia is observed in almost half of all cancer patients being treated with chemotherapy, but of those, most are suffering from leukemia. According to medical experts, neutropenia can be a chronic condition because, without adequate neutrophils, patients become vulnerable to life-threatening infections.

Market Synopsis

A strong drug pipeline will assist the significant growth of the neutropenia treatment market throughout the forecast period.

The drug pipeline for neutropenia treatment is equipped with several promising drugs in phase III of clinical trials, such as SPI-2012 (Spectrum Pharmaceuticals, Inc.), F-627 (Generon Shanghai Corporation Ltd.), Leucostim (Dong-A ST Co., Ltd.), myelo001 (Myelo Therapeutics, Inc.), Plinabulin (BeyondSpring Pharmaceuticals, Inc.), and Romyelocel-L (Cellerant Therapeutics, Inc.).

Neutropenia is caused by several factors, the major one being the post-chemotherapy decrease in neutrophil count. An increasing prevalence of leukemia is expected to raise the number of neutropenia cases, as chemotherapy is the first-line treatment for leukemia. However, a precautionary treatment regimen is ready to avoid the effects of neutropenia-based infections with antibacterial, antiviral, and antifungal drugs.

North America dominated the overall global market specifically due to a promising drug pipeline and a developed diagnostic landscape.

In 2018, North America dominated the market and was expected to retain its position throughout the forecast period due to rising awareness related to neutropenia, the increasing prevalence of side effects related to chemotherapy during leukemia treatment, and high expectations from drugs in the pipeline.

According to several studies, the prevalence of neutropenia is around 4.4% and is expected to increase in specific regions with the rising prevalence of leukemia. During the forecast period from 2019 to 2027, Asia Pacific will grow gradually due to increasing awareness related to neutropenia diagnosis and treatment, coupled with the development of diagnostic technologies in the rare disease sector.

Historical and Forecast Period

The neutropenia treatment market was analyzed considering current market trends for the base year of 2018, and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report comprises detailed qualitative and quantitative data related to the neutropenia treatment market, along with key factors related to the market, such as opportunities, drivers, and restraints. An elaborative analysis covering market drivers, challenges, and opportunities is provided explicitly for country-level and regional segmentation.

This report covered brief information associated with the global neutropenia treatment market segmented by such factors as drug class, type, and geography. The pipeline analysis of the neutropenia treatment market comprises drugs under trial in preclinical studies phases I, II, and III. Competitive analysis of the major companies is included in the neutropenia treatment market, along with detailed data related to the competitive landscape of the market and recent strategies and products entering the market.

The key companies included in the neutropenia treatment industry were analyzed based on financial data, product portfolios, current press releases, and major market strategies. This report also includes attractive investment propositions studied based on exclusive geographical PESTEL analysis. Major companies included in the report are Amgen, Inc.; Spectrum Pharmaceuticals, Inc.; Generon (Shanghai) Corporation Ltd.; Dong-A ST Co., Ltd.; BeyondSpring Pharmaceuticals, Inc.; Myelo Therapeutics, Inc.; Cellerant Therapeutics, Inc.; and Sandoz (a subsidiary of Novartis AG), among others.

Key questions are answered in this report.

  • Which is the most frequent drug class to manage and treat neutropenia, and why?
  • What are the novel marketing strategies followed by the major companies and the competitive landscape of the neutropenia treatment market?
  • Which are the recent and upcoming drugs in the neutropenia treatment market?
  • Which is the largest and fastest-growing neutropenia treatment segment globally?
  • What are the drivers, restraints, and opportunities in the neutropenia treatment market?
  • Which are the major geographical markets (regions and countries) of the neutropenia treatment market?

 Frequently Asked Question:

The market for Neutropenia Treatment Market is expected to reach USD$ 11,279.2 Mn in 2027.

The Neutropenia Treatment Market is expected to see significant CAGR growth over the coming years, at 5.0%

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

Amgen, Inc.; Spectrum Pharmaceuticals, Inc.; Generon (Shanghai) Corporation Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2019
Category:  Pharmaceuticals
Report ID:   59839
Report Format:   PDF
Pages:   120
Rating:    4.1 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support